Publications
Publications
Show Results For
- All HBS Web
(343)
- Faculty Publications (153)
- August 2001
- Case
Finnigan Corporation
By: Carliss Y. Baldwin and Barbara Feinberg
Finnigan Corp., headquartered in San Jose, CA, was the world's leading producer of mass spectrometers, holding a 45% market share of instruments used for chemical analysis in pharmaceutical product development, environmental testing, genetic testing, and other... View Details
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (A)
By: Michael Beer and James Weber
Introduces Grey Warner, the vice president of Merck's Latin America region, and his efforts to improve the organizational effectiveness of the region and to introduce a more global business culture and values. Discusses Merck's ethics and values, its Latin American... View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (C): Brazil
By: Michael Beer and James Weber
Examines Merck's change effort in Brazil from the perspective of the local employees. View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (D): Mexico
By: Michael Beer and James Weber
Examines Merck's change effort in Mexico from the perspective of the local employees. View Details
- March 2001 (Revised June 2017)
- Teaching Note
Vyaderm Pharmaceuticals: The EVA Decision
By: Robert Simons and Indra A. Reinbergs
Teaching Note for (9-101-019). View Details
- October 2000
- Case
Procter & Gamble Italy: The Pringles Launch (A)
By: Roy D. Shapiro
Procter & Gamble's (P&G) Pringles potato chips have been a very successful brand. This case reviews the development and first launch in the United States, then in markets around the world. Italy is one of the last countries where Pringles will be launched. Should P&G... View Details
- October 2000 (Revised June 2017)
- Case
Vyaderm Pharmaceuticals: The EVA Decision
By: Robert Simons and Indra A. Reinbergs
In 2016, the new CEO of Vyaderm Pharmaceuticals introduces an Economic Value Added (EVA) program to focus the company on long-term shareholder value. The EVA program consists of three elements: EVA centers (business units), EVA drivers (operational practices that... View Details
- December 1999 (Revised August 2001)
- Case
Millennium Pharmaceuticals, Inc. (A)
By: Stefan H. Thomke and Ashok Nimgade
Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details
- March 1999
- Case
Merck & Co., Inc.: Corporate Strategy, Organization and Culture (A)
By: Michael Beer and Perry Fagan
In the early 1990s, Merck faced a series of challenges because of significant changes in its competitive and regulatory environment (e.g., growth in power of pharmaceutical buyers like managed care organizations led to price pressures and President Clinton's review of... View Details
Keywords: Organizational Change and Adaptation; Business or Company Management; Organizational Culture; Problems and Challenges; Management Practices and Processes; Competitive Strategy; Management Teams; Health Care and Treatment; Governing Rules, Regulations, and Reforms; Situation or Environment; Alignment; Pharmaceutical Industry; United States
- April 1998
- Case
Cephalon, Inc.
By: Peter Tufano
In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details
- February 1998 (Revised October 1998)
- Background Note
Note on New Drug Development in the United States
By: Stefan H. Thomke and Ashok Nimgade
An overview of the new drug development process in the United States, using the migraine drug Imitrex as an illustrative example. View Details
- November 1997 (Revised November 2010)
- Case
Hikma Pharmaceuticals (A)
By: John A. Quelch
The president of a Jordanian pharmaceutical company is contemplating how to further penetrate the U.S. market, either through its own manufacturing and sales efforts, or as a supplier to a third party. View Details
- September 1997 (Revised October 1997)
- Case
Bayer AG (A)
By: John A. Quelch
Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details
- February 1997 (Revised June 1999)
- Teaching Note
Massachusetts General Hospital: CABG Surgery (A) TN
Teaching Note for (9-696-015). View Details
- January 1997 (Revised July 1998)
- Case
Dendrite International (Condensed)
By: John A. Deighton
This version has been shortened to concentrate on the issue of managing a long selling process and long post-sale account relationship. The focus on the pharmaceutical industry in the United States, Europe, and Japan is preserved. Broader questions of expansion into... View Details
- December 1996 (Revised June 2003)
- Case
Cynthia Hogan and the Birth of Novartis
An American woman heads an integration office for merger transition activities between two giant Swiss pharmaceutical companies. She needed to develop an implementation plan to shape the new global powerhouse. View Details
- November 1995 (Revised March 2004)
- Case
Massachusetts General Hospital: CABG Surgery (A)
By: Steven C. Wheelwright and James Weber
A cross-functional team at Massachusetts General Hospital tries to reengineer the service delivery process (the "care path") for heart bypass surgery (CABG) in order to shorten hospital stays (and lower costs) while maintaining/enhancing the quality of care provided. View Details
Keywords: Health Care and Treatment; Medical Specialties; Business Processes; Mission and Purpose; Product Positioning; Product Marketing; Management Practices and Processes; Customer Satisfaction; Service Delivery; Service Operations; Fair Value Accounting; Ethics; Pharmaceutical Industry; Pharmaceutical Industry; Massachusetts
- December 1994 (Revised March 1996)
- Case
Ciba Consumer Pharmaceuticals' Acutrim: Challenges and Opportunities in Today's Diet Industry
By: Nancy F. Koehn and Rebecca Voorheis
Since its introduction in 1983, Acutrim has been a major player in the U.S. appetite suppressant market and in the broader diet industry. This case focuses on the strategic, regulatory, marketing, and financial challenges this product and the rapidly changing diet... View Details